2017 Economic Report on Pharmacies and Pharmacy Benefit Managers (known in our previous editions as The Economic Report on Retail, Mail, and Specialty Pharmacies)
The exhibit below—one of 143 in our new report—provides a first look at the largest pharmacies, ranked by total U.S. prescription dispensing revenues for calendar year 2016. As you will see, the growth of specialty drugs is reshaping the pharmacy and PBM industries.
For a sneak peek at the complete report, download the free overview. Enjoy!
The table below shows the largest pharmacies ranked by total prescription dispensing revenues from retail, mail, long-term care, and specialty pharmacies. The top tier of dispensing pharmacies—CVS Health, Walgreens Boots Alliance (WBA), Express Scripts, Walmart, Rite Aid, and OptumRx (UnitedHealth)—accounted for about 62% of U.S. prescription dispensing revenues in 2016.
[Click to Enlarge]
PBM-owned and insurer-owned central-fill mail pharmacies with substantial specialty operations constitute six of the of the industry's largest 15 pharmacies. Retail pharmacies that focus on traditional drugs account for a majority of the industry’s dispensed prescriptions but a decreasing share of the industry’s revenues. In our 2017 Economic Report on Pharmacies and Pharmacy Benefit Managers, we analyze the developments behind these market share figures.
Note that our analysis now includes long-term care pharmacies. Consequently, market-share figures are not comparable with previous figures. In the report, we have restated the historical data to reflect this broader market definition.
There are at least three reasons our estimated prescription revenue data may not correspond with other public sources:
- Wherever possible, we have computed figures on a calendar-year basis. The fiscal years for many public retail companies do not correspond to the calendar year.
- Many companies do not report prescription revenues. We have therefore used various methods and sources to estimate the data
- As noted in the footnotes, we have made various adjustments to account for the pro forma impact of mergers and acquisitions.